Lenvatinib

본문 바로가기


Home > Product > Lenvatinib
Selling leads
Lenvatinib
Posting date : Aug 29, 2025
Membership
Free Member Scince Jun 27, 2025
FOB Price
detailed discussion
Min. Order Quantity
1
Supply Abillity
hundreds of kgs
Port
Shanghai Port
Payment Terms
detailed discussion
Package
Convenient package
Keyword :
Category
Contact
Lena
Selling Leads Detail
Company Info
 
Quick Detail
Place of Origin
China [CN]
Brand Name
Royal
Model Number
+86 15242851296
HS-CODE
-
Package & Delivery Lead Time
Package
Convenient package
Detailed Description

lenvatinib, trade name Lenvima, is an oral multi-target tyrosine kinase (RTK) inhibitor. Besides inhibiting RTKS related to pro-angiogenic and carcinogenic signaling pathways, it can also selectively inhibit the kinase activity of vascular endothelial growth factor (VEGF) receptors. The Chemicalbook includes VEGF1, VEGF2, VEGF3, as well as FGFR, PDGFRα, KIT and RET. This drug was approved by the US FDA for marketing on February 13, 2015, and is used to treat locally recurrent or metastatic, radioactive iodine-refractory, and progressive differentiated thyroid cancer (DTC).


ECROBOT CO., Ltd, Business Registration Number : 220-88-71747, CEO J.W.Park, TEL : +82-2-552-7676, E-mail : E-mail : Contact us
Address : (Hwanghwa B/D 11F, Yeoksam-dong)320, Gangnam-daero, Gangnam-gu, Seoul, South Korea
About Us Privacy Policy Terms of use Copyright © 2000-2026 ECROBOT.COM. All rights reserved.
Top